BRN2与NOTCH1/2信号通路的相互调控协同驱动黑色素瘤细胞迁移和侵袭
研究探讨黑色素瘤中BRN2与NOTCH1/2信号的相互关系及其驱动侵袭表型的机制。在体外黑色素瘤细胞、患者数据集及体内原发和转移性人肿瘤中均发现BRN2与NOTCH1/2信号存在反向关系,该轴通过表观遗传调节因子EZH2维持侵袭表型,并可能作为预测治疗反应和预防转移的生物标志物。
要点
- BRN2与NOTCH1/2信号在黑色素瘤细胞、患者数据集及体内肿瘤中呈反向关系。
- BRN2–NOTCH1/2轴通过EZH2表观遗传调节因子维持侵袭表型。
- 该轴可能提供预测治疗反应和预防转移的关键生物标志物。
核心结论
- BRN2与NOTCH1/2信号之间的反向关系在体外黑色素瘤细胞、患者数据集及体内原发和转移性人肿瘤中存在,并增强侵袭性的获得。
- BRN2–NOTCH1/2轴通过表观遗传调节因子EZH2发挥作用,可能是维持侵袭表型的关键机制。
- 理解BRN2促进异质性的机制可能提供预测治疗反应和预防转移的关键生物标志物。
研究设计与样本
- 研究在体外黑色素瘤细胞、患者数据集以及体内原发和转移性人肿瘤中评估BRN2与NOTCH1/2信号的关系。
- 原文未报告样本量、分组和研究类型等具体设计信息。
主要发现
- 在体外黑色素瘤细胞、患者数据集及体内原发和转移性人肿瘤中均发现BRN2与NOTCH1/2信号存在反向关系,该关系增强侵袭性的获得。
- BRN2–NOTCH1/2轴通过表观遗传调节因子EZH2发挥作用,可能是维持侵袭表型的关键机制。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Phenotypic plasticity drives cancer progression, impacts treatment response, and is a major driver of therapeutic resistance. In melanoma, a regulatory axis between the MITF and BRN2 transcription factors has been reported to promote tumor heterogeneity by mediating switching between proliferative and invasive phenotypes, respectively. Despite strong evidence that subpopulations of cells that exhibit a BRN2high/MITFlow expression profile switch to a predominantly invasive phenotype, the mechanisms by which this switch is propagated and promotes invasion remain poorly defined. We have found that a reciprocal relationship between BRN2 and NOTCH1/2 signaling exists in melanoma cells in vitro, within patient datasets, and in in vivo primary and metastatic human tumors that bolsters acquisition of invasiveness. Working through the epigenetic modulator EZH2, the BRN2‒NOTCH1/2 axis is potentially a key mechanism by which the invasive phenotype is maintained. Given the emergence of agents targeting both EZH2 and NOTCH, understanding the mechanism through which BRN2 promotes heterogeneity may provide crucial biomarkers to predict treatment response to prevent metastasis.
引用
- Fane ME, Chhabra Y, Spoerri L, et al. Reciprocal Regulation of BRN2 and NOTCH1/2 Signaling Synergistically Drives Melanoma Cell Migration and Invasion. J Invest Dermatol. 2021. PMID: 34958806. doi:10.1016/j.jid.2020.12.039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。